YKL-40

YKL-40 (YKL-40)

YKL-40, also known as Chitinase-3-like protein 1, is a carbohydrate-binding lectin with a preference for chitin. It plays a role in defense against pathogens and in tissue remodeling. YKL-40 is thought to play an important role in the capacity of cells to respond to and cope with changes in their environment. It is a potent growth factor for connective tissue cells and acts as a migration factor for endothelial cells. YKL-40 is present in activated macrophages, articular chondrocytes, synovial cells, and the liver. It is undetectable in muscle tissues, lung, pancreas, mononuclear cells, or fibroblasts. YKL-40 binds chitins; however, it has no chitinase activity. Elevated serum levels are seen in arthritis, severe bacterial infection, inflammatory bowel disease, and various cancers.

Swiss-Prot Accession Number: P36222

Publications

Degree of Genetic Liability for Alzheimer?s Disease Associated with Specific Proteomic Profiles in Cerebrospinal Fluid (2020) Reus LM, Stringer S, Posthuma D, Teunissen CE, Scheltens P, Pijnenburg YAL, Visser PJ, Tijms BM, for the Alzheimer's Disease Neuroimaging Neurology of Aging

APOE e4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer?s disease (2020) Konijnenberg E, Tijms BM, Gobom J, Dobricic V, Bos I, Vos S, Tsolaki M, Verhey F, Popp J, Martinez-Lage P, Vandenberghe R, Lleo A, Frolich L, Lovestone S, Streffer J, Bertram L, Blennow K, Teunissen CE, Veerhuis R, Smit AB, Scheltens P, Zetterberg H, Visser PJ Alzheimer's Research & Therapy

Molecular biomarkers of anti-TNF response in patients with rheumatoid arthritis (2020) Yoosuf N, Maciejewski M, Ziemek D, Jelinsky S, Folkersen, Muller M, Sahlstrom P, Vivar N, Catrina A, Berg L, Klareskog L, Padyukov L, Brynedal B Arthritis Research & Therapy

Dendritic cell immunotherapy followed by cART interruption during HIV-1 infection induces plasma protein markers of cellular immunity and neutrophil recruitment (2018) van den Ham HJ, Cooper J, Tomasik J, Bahn S, Aerts J, Oseterhaus A, Gruters R, Andeweg A PLoS One

Pegbelfermin (BMS-986036), PEGlyated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study (2018) Charles ED, Neuschwander-Tetri BA, Pablo Frias J, Kundu S, Luo Y, Tirucherai GS, Christrian R Obesity (Silver Spring)

Neuronal Pentraxin 2 predicts medial temporal atrophy and memory decline across the Alzheimer's disease spectrum. (2017) Swanson A, Willette AA; Alzheimer?s Disease Neuroimaging Initiative. Brain Behav Immun.

Baseline results of the NeuroNEXT spinal muscular atrophy infant biomarker study (2016) Kolb SJ, Coffey CS, Yankey JW, Krosschell K, Arnold WD, Rutkove SB, Swoboda KJ, Reyna SP, Sakonju A, Darras BT, Shell R, Kuntz N, Castro D, Iannaccone ST, Parsons J, Connolly AM, Chiriboga CA, McDonald C, Burnette WB, Werner K, Thangarajh M, Shieh PB, Finanger E, Cudkowicz ME, McGovern MM, McNeil DE, Finkel R, Kaye E, Kingsley A, Renusch SR, McGovern VL, Wang X, Zaworski PG, Prior TW, Burghes AH, Bartlett A, Kissel JT Ann Clin Transl Neurol

Variation in Serum Biomarkers with Sex and Female Hormonal Status: Implications for Clinical Tests (2016) Ramsey JM, Cooper JD, Penninx BWJH, Bahn S Scientific Reports

Least absolute shrinkage and selection operator type methods for the identification of serum biomarkers of overweight and obesity: simulation and application. (2016) Vasquez MM, Hu C, Roe DJ, Chen Z, Halonen M, Guerra S BMC Med Res Methodol

Identifying Novel Biomarkers for Cardiovascular Events or Death in People with Dysglycemia (2015) Gerstein HC, Par? G, Mcqueen MJ, Haenel H, Lee SF, Pogue J, Maggioni AP, Yusuf S, Hess S Circulation

Comprehensive serum profiling for the discovery of epithelial ovarian cancer biomarkers (2011) Yip P, Chen TH, Seshaiah P, Stephen LL, Michael-Ballard KL, Mapes JP, Mansfield BC, Bertenshaw GP PLoS One. 2011;6(12):e29533. Epub 2011 Dec 21